28 September 2021
SpeeDx announces investment in SynGenis
SpeeDx announced investment in SynGenis Pty Ltd., an experienced oligonucleotide manufacturer based in Western Australia. The partnership will bolster internal capacity...
1 September 2021
SpeeDx included in new PHE National Microbiology Framework
SpeeDx has been included in the new Public Health England (PHE) National Microbiology Framework to supply Diagnostic goods and services...
17 August 2021
SARS-CoV-2 Variant Analysis Portfolio Expanded
SpeeDx have expanded their product line of research reagents for COVID-19 variant analysis to include a mutation connected to the...
12 August 2021
SpeeDx receives TGA clearance PlexPCR® SARS-CoV-2
SpeeDx Pty. Ltd. announced today their PlexPCR® SARS-CoV-2* test received clearance from the Australian Therapeutic Goods Administration (TGA). Designed from...
5 August 2021
SpeeDx Expand US Operations with New Laboratory Facility
SpeeDx announced the expansion of US based operations and will initiate construction of clinical testing facilities in Austin, Texas. The...
26 July 2021
SpeeDx launches PlexPrime® SARS-CoV-2 Genotyping research reagents
SpeeDx have launched a new product line of research reagents to support reflex variant analysis for circulating SARS-CoV-2 variants of...